Replies to post #90415 on Decision Diagnostics Corp (DECN)

[IPwatcher]

that already has FDA approved products for diabetes.

They have never successfully completed their own regulatory submission. One was completed by the company whose assets they acquired through litigation and toll manufctured by a South Korean partner. Another is a rebadged Chinese manufactured product and the 510K is that of the chinese OEM company.

Using the same technology / methodology Pharmatech Solutions claims to have created a new test strip capable of instead testing for the Covid-19 virus (antigen)

They are lying.

If DECN successfully creates this product

It can't and won't. The technology is unfeasible.

I hope DECN's claims are true.

They aren't. Berman has an established track record of over promising and under delivering. As well as diluting shareholders to waste in the process with share issues and reverse splits while insiders and Berman associated are featherbedded and issued discounted options.

[pumper_stumper]

You DO realize that their diabetes products are so pathetic that:

1) They are not covered by most health insurance plans in the USA

2) That DECN has lost, and will continue to lose MILLIONS of dollars selling these tests.

In many cases, like this one, pink sheet investors seem to think that business is some kind of Junior High science contest, where the objective is just to create a product (actually, as IPwatcher noted, in this case the creation of the product wasn't even Berman's doing! So he wouldn't even have won the junior high science contest! lol)

In the REAL world, there is a "strange concept" (to pink sheet investors). It's called profitability. And so, having an "FDA approved product" does nothing but allow the company to incur losses!

What is your estimate for company losses to be announced this week?

Can I guess, "this is the pink sheets, so it doesn't matter", right? ;-)